Literature DB >> 32375168

Comment on: Clinical characteristics and comorbidities in adult-onset Still's disease using a large US administrative claims database: reply.

Aleksander Lenert1, GYeon Oh2, Michael J Ombrello3, Sujin Kim4.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32375168      PMCID： PMC7849978          DOI： 10.1093/rheumatology/keaa154

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  6 in total

1.  Macrophage activation syndrome complicating adult onset Still's disease: A single center case series and comparison with literature.

Authors:  Aleksander Lenert; Qingping Yao
Journal:  Semin Arthritis Rheum       Date:  2015-11-10       Impact factor: 5.532

2.  Preliminary criteria for classification of adult Still's disease.

Authors:  M Yamaguchi; A Ohta; T Tsunematsu; R Kasukawa; Y Mizushima; H Kashiwagi; S Kashiwazaki; K Tanimoto; Y Matsumoto; T Ota
Journal:  J Rheumatol       Date:  1992-03       Impact factor: 4.666

3.  Accuracy of US Administrative Claims Codes for the Diagnosis of Autoinflammatory Syndromes.

Authors:  Aleksander Lenert; Maranda J Russell; Suzanne Segerstrom; Sujin Kim
Journal:  J Clin Rheumatol       Date:  2020-02-05       Impact factor: 3.517

4.  Comment on: Clinical characteristics and comorbidities in adult-onset Still's disease using a large US administrative claims database.

Authors:  Alojzija Hočevar; Matija Tomšič; Žiga Rotar
Journal:  Rheumatology (Oxford)       Date:  2020-07-01       Impact factor: 7.580

5.  Clinical characteristics and comorbidities in adult-onset Still's disease using a large US administrative claims database.

Authors:  Aleksander Lenert; GYeon Oh; Michael J Ombrello; Sujin Kim
Journal:  Rheumatology (Oxford)       Date:  2020-07-01       Impact factor: 7.580

Review 6.  Life-threatening complications of adult-onset Still's disease.

Authors:  Petros Efthimiou; Sabeeda Kadavath; Bella Mehta
Journal:  Clin Rheumatol       Date:  2014-01-17       Impact factor: 2.980
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.